Gene Expression Profile of Peripheral Blood Lymphocytes from Renal Cell Carcinoma Patients Treated with IL-2, Interferon-α and Dendritic Cell Vaccine

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Wolf, Benita ^a,b,c   Schwarzer, Adrian ^a,b,c   Côté, Anik L ^a   Hampton, Thomas H ^e   Schwaab, Thomas ^a,d   Huarte, Eduardo ^f   Tomlinson, Craig R ^e   Gui, Jiang ^e   Fisher, Jan L ^a,e   Fadul, Camilo E ^a,e   Hamilton, Joshua W ^g   Ernstoff, Marc S ^a,e  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c Hannover Biomedical Research School   (Germany)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f MONTANA STATE UNIVERSITY   (United States)

^g MARINE BIOLOGICAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BIOLOGICAL MARKER; DENDRITIC CELL VACCINE; INTERLEUKIN 2; MESSENGER RNA; ALPHA INTERFERON; CANCER VACCINE; CYTOKINE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; MALE; METASTASIS; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PERIPHERAL LYMPHOCYTE; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; BLOOD; CLUSTER ANALYSIS; DENDRITIC CELL; DNA MICROARRAY; GENETICS; IMMUNOLOGY; KIDNEY TUMOR; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; METABOLISM; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION;

CANCER VACCINES; CARCINOMA, RENAL CELL; CLUSTER ANALYSIS; CYTOKINES; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; LYMPHOCYTE SUBSETS; LYMPHOCYTES; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84868283852     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050221     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
3. Ardavin C, Amigorena S, Reis e Sousa, (2004) Dendritic cells: immunobiology and cancer immunotherapy. Immunity 20: 17-23.
4. Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, et al. (2007) Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res 13: 667s-670s.
5. Motzer RJ, Molina AM, (2009) Targeting renal cell carcinoma. J Clin Oncol 27: 3274-3276.
6. Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, et al. (2010) Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int 106: 772-778. BJU9218 [pii];10.1111/j.1464-410X.2010.09218.x [doi].
7. Clement JM, McDermott DF, (2009) The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 7: E7-E9.
8. Burczynski ME, Twine NC, Dukart G, Marshall B, Hidalgo M, et al. (2005) Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res 11: 1181-1189.
9. Twine NC, Stover JA, Marshall B, Dukart G, Hidalgo M, et al. (2003) Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res 63: 6069-6075.
10. Chaussabel D, Allman W, Mejias A, Chung W, Bennett L, et al. (2005) Analysis of significance patterns identifies ubiquitous and disease-specific gene-expression signatures in patient peripheral blood leukocytes. Ann N Y Acad Sci 1062: 146-154.
11. Dedrick RL, (2007) Understanding gene expression patterns in immune-mediated disorders. J Immunotoxicol 4: 201-207.
12. Edwards CJ, Feldman JL, Beech J, Shields KM, Stover JA, et al. (2007) Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis. Mol Med 13: 40-58.
13. Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, et al. (2009) Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res 15: 4986-4992.
14. Panda A, Arjona A, Sapey E, Bai F, Fikrig E, et al. (2009) Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol 30: 325-333.
15. Woodland DL, Blackman MA, (2006) Immunity and age: living in the past? Trends Immunol 27: 303-307.
16. Kondo T, Nakazawa H, Ito F, Hashimoto Y, Osaka Y, et al. (2006) Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 97: 780-786.
17. Jaffe CC, (2006) Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24: 3245-3251.
18. Hampton TH, Stanton BA, (2010) A novel approach to analyze gene expression data demonstrates that the DeltaF508 mutation in CFTR downregulates the antigen presentation pathway. Am J Physiol Lung Cell Mol Physiol 298: L473-L482.
19. Meyer K, Beckman JM (2008) Design and Analysis of Micrarray Experiments. In: Mechanistic Toxicogenomics. West Sussex, United Kingdom: John Wiley and Sons. 3-26.
20. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, et al. (2006) The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24: 1151-1161.
21. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
22. Soh D, Dong D, Guo Y, Wong L, (2010) Consistency, comprehensiveness, and compatibility of pathway databases. BMC Bioinformatics 11: 449.
23. Everitt BS, Landau S, (1998) The use of multivariate statistical methods in psychiatry. Stat Methods Med Res 7: 253-277.
24. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, et al. (2000) Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A 97: 3260-3265.
25. Schwarzer A, Wolf B, Fisher JL, Schwaab T, Olek S, et al. (2012) Regulatory T-cells and associated pathways in metastatic Renal Cell Carcinoma (mRCC) Patients undergoing DC-vaccination and cytokine-therapy. PLoS One 7: e46600.
26. Hirano S, Iwashita Y, Sasaki A, Kai S, Ohta M, et al. (2007) Increased mRNA expression of chemokines in hepatocellular carcinoma with tumor-infiltrating lymphocytes. J Gastroenterol Hepatol 22: 690-696.
27. Cardi G, Heaney JA, Schned AR, Phillips DM, Branda MT, et al. (1997) T-cell receptor zeta-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma. Cancer Res 57: 3517-3519.
28. Cardi G, Heaney JA, Schned AR, Ernstoff MS, (1998) Expression of Fas(APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. Cancer Res 58: 2078-2080.
29. Ernstoff MS, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, et al. (2007) Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang. Clin Cancer Res 13: 733s-740s.
30. Ochoa AC, Longo DL (1995) Alteration of signal transduction in T cells from cancer patients. Important Adv Oncol 43-54.
31. Radich JP, Mao M, Stepaniants S, Biery M, Castle J, et al. (2004) Individual-specific variation of gene expression in peripheral blood leukocytes. Genomics 83: 980-988.
32. Wu Y, Fu X, Zhu X, He X, Zou C, et al. (2011) Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol 137: 887-896.
33. Bukowski RM, Rayman P, Uzzo R, Bloom T, Sandstrom K, et al. (1998) Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. Clin Cancer Res 4: 2337-2347.
34. Donskov F, von der MH, (2006) Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 24: 1997-2005.
35. Stanley AC, Lacy P, (2010) Pathways for Cytokine Secretion. Physiology 25: 218-229.
36. Crocenzi TS, Tretter CP, Schwaab T, Schned AR, Heaney JA, et al. (2005) Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients. Clin Immunol 117: 6-11.
37. Friedline RH, Brown DS, Nguyen H, Kornfeld H, Lee J, et al. (2009) CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 206: 421-434.
38. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
39. Quezada SA, Peggs KS, Curran MA, Allison JP, (2006) CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116: 1935-1945.
40. Sitkovsky M, Lukashev D, (2005) Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. Nat Rev Immunol 5: 712-721.
41. Buza-Vidas N, Cheng M, Duarte S, Nozad H, Jacobsen SE, et al. (2007) Crucial role of FLT3 ligand in immune reconstitution after bone marrow transplantation and high-dose chemotherapy. Blood 110: 424-432.
42. Harada S, Kimura T, Fujiki H, Nakagawa H, Ueda Y, et al. (2007) Flt3 ligand promotes myeloid dendritic cell differentiation of human hematopoietic progenitor cells: possible application for cancer immunotherapy. Int J Oncol 30: 1461-1468.
43. Lyman SD, Jacobsen SE, (1998) c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 91: 1101-1134.
44. Kojima H, Sitkovsky MV, Cascalho M, (2003) HIF-1 alpha deficiency perturbs T and B cell functions. Curr Pharm Des 9: 1827-1832.
45. Vecchiarelli-Federico LM, Cervi D, Haeri M, Li Y, Nagy A, et al. (2010) Vascular endothelial growth factor-a positive and negative regulator of tumor growth. Cancer Res 70: 863-867.
46. Baehner FL, Lee M, Demeure MJ, Bussey KJ, Kiefer JA, et al. (2011) Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy. J Surg Oncol 103: 563-573.
47. Mutch MG, (2007) Molecular profiling and risk stratification of adenocarcinoma of the colon. J Surg Oncol 96: 693-703.
48. Lacroix L, Commo F, Soria JC, (2008) Gene expression profiling of non-small-cell lung cancer. Expert Rev Mol Diagn 8: 167-178.
49. Vuillaume ML, Uhrhammer N, Vidal V, Vidal VS, Chabaud V, et al. (2009) Use of Gene Expression Profiles of Peripheral Blood Lymphocytes to Distinguish BRCA1 Mutation Carriers in High Risk Breast Cancer Families. Cancer Inform 7: 41-56.
50. Angevin E, Farace F, Genevee C, Henry-Amar M, Caignard A, et al. (1993) Analysis of T-cell-receptor variable gene segment usage in peripheral-blood lymphocytes of advanced cancer patients. Int J Cancer 54: 60-67.
51. Bhardwaj N, (2007) Harnessing the immune system to treat cancer. J Clin Invest 117: 1130-1136.